SCHEMBL930138

SCHEMBL930138

CCOC(=O)C(=O)Cc1nccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
PKM P14618 4/20 0.56
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
GAA P10253 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.48
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
FDPS P14324 1/20 0.39
NPC1 O15118 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658210 0.83 PKM (0.51) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL8056605 0.76 ALDH1A1 (0.68) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL5270765 0.76 ALDH1A1 (0.56) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL4759129 0.76
SCHEMBL8358249 0.75 L3MBTL1 (0.44) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL5043060 0.75 FDPS (0.43) ALDH1A1PKMMAPTMEN1KMT2A
SCHEMBL16466030 0.75 PKM (0.58) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL3219037 0.75 ALDH1A1 (0.58) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL20703021 0.74 CTDSP1 (0.55) ALDH1A1PKMMAPTMEN1GAA
SCHEMBL6959399 0.74 HTT (0.46) ALDH1A1PKMMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875600-B2 Pyrimidine compounds as purine receptor antagonist VERNALIS (R&D) LIMITED (GB) 2011-01-25 US disclosed
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide VERNALIS (R & D ) LIMITED (GB) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide ADORA2A, ADORA3, ADORA1 ALDH1A1 562/4885PKM 1856/4885MAPT 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.